


tea.mit

RESEARCH



ANNUAL REPORT

2021

CONTENT

01

European
Context

04

Projects
Highlights

02

2021

At a Glance:
Our Key
Achievements

05

Partnerships
Highlights

03

Corporate
Highlights

06

The Year
Ahead

A WORD

From the CEO



“For Teamit, 2021 was a period of expansion due to the global demands placed on the health research ecosystem. It was also a year in which we managed to lay solid foundations for a sustained growth based on excellence and innovation by widening our team of experts and creating a solid quality framework.”

Driven by global demands placed on the health research ecosystems, the need for sound expertise in the scientific coordination and management of leading international partnerships and initiatives is unquestionable. Indeed, the pandemic has forced a collaborative approach in clinical research to advance on common solutions to global health challenges. This new reality further strengthens the relevance of international public-private partnerships (PPP).

Our long-term experience in this field was put to good use during 2021 in far-reaching initiatives and studies where we had the opportunity to build strong operational strategies and closely support investigation and innovation.

In this context, Teamit registered a swift growth driven by excellence in all the areas we are involved in: management of research projects and international pharmacoepidemiology studies, risk management, consortia and network governance, communication and dissemination, knowledge transfer or sustainability and exploitation.

Concurrently, we welcomed Horizon Europe (HE), the new EU flagship funding programme for research and innovation replacing Horizon 2020. HE kicked off with an overall budget of nearly EUR 97 billion until 2027.



We were glad to ascertain that HE reinforces the strategic value of Open Science and PPPs, areas where Teamit Research is strong. We submitted our firsts competitive proposals, under this new funding programme in September 2021 with successful results. Internally, we focused on laying solid foundations to underpin the ever-growing demand for our services in increasingly ambitious global research initiatives which are based on international, multistakeholder collaboration.

A major milestone for the company, was the creation of Teamit Institute, a spin off of Teamit Research aimed at consolidating our activity on pharmacovigilance and regulatory science.

Externally, we continued nurturing strong ties with leading research organisations from the public and private sector. Building long term relationships based on trust and excellence is at the core of our business and the driving force behind cutting-edge research.

- Eva Molero 

EUROPEAN CONTEXT



The program Horizon Europe (HE) replaced Horizon 2020 to fulfil the EU vision on fostering cutting-edge research and innovation global leadership. With an overall budget of €95,5 billion, this new framework brought important changes. Teamit closely followed HE negotiations and its initial roll out to ensure this transition was captured and properly embedded in our activities.

We highlight these main changes introduced by HE:

- Strengthening **International cooperation** by allowing association agreements beyond Europe.
- Consolidation of **Open Science** policies to enhance cooperation and systematic sharing of knowledge and tools.
- Reinforcement of **impact**, recognising the important role of communication, dissemination and exploitation in translating innovative projects' results into real benefits for society.
- Rationalisation of previous **partnerships** to nine strategic joint undertakings to make them more efficient.

between the EU and the United Kingdom introduced a new element of uncertainty. The commitment of the United Kingdom Research & Innovation (UKRI) to guarantee funding to all UK successful HE applicants has temporarily resolved this issue.



During 2021, Teamit Research already participated in the inception, design and submission of HE proposals with positive outcomes. REMEDI₄ALL is the first HE funded initiative in which Teamit will play a strategic role in the years to come.

The absence of a formal HE association agreement

2021 AT A GLANCE



**Creation of
teamit**
INSTITUTE



PROMISE

**Start of IMI
PROMISE
Project**



CORPORATE HIGHLIGHTS

Teamit swift growth has been accompanied by the development of new resources, instruments and procedures to ensure a smooth expansion of our team and business areas. Internally, we focused on sustaining our commitment toward excellence and continuous learning and improvement. Attaining the ISO 9001 Certificate was a major step in this direction. This certificate came as an endorsement to our quality systems which we see as key to cement an excellence-based growth. The company also continued to nurture its connections with the Barcelona Health Hub ecosystem.

In 2021, we also welcomed four new members to our team who brought expertise in the areas of scientific research management and pharmacoepidemiology. In parallel, a capacity building plan for all employees kicked off in 2021 touching on soft and technical skills.

KEY ACHIEVEMENTS

Granted ISO 9001 certificate, endorsing Teamit Research quality systems to cement excellence-based growth.

Corporate Social Responsibility activities supporting a more equitable, sustainable, healthier and inclusive world. Women in Science; Earth Day; World Immunisation week.

Teamit Research joins VAC4EU membership, the sustainability solution of IMI Advance project in which some of Teamit's staff were already involved.

Growing team and areas of expertise.

Capacity building activities to meet new requirements with people-oriented approach.

Communication and dissemination reinforced as a new business area, to continue driving impact in European R&D proposals and projects.

Co-authorship in different scientific publications.


Training activities on EU Research Project management delivered to different organisations.

OUR CURRENT PROJECTS AND STUDIES FOCUS ON:



PROJECTS HIGHLIGHTS

- Preparation and submission of first **HE proposals** as partners.
- **Consultancy** services to different institutions and consortia.
- Final reporting and closing of the **PARADIGM** project with the celebration of the Patient Engagement Open Forum (PEOF).



PROMISE

Preparing for RSV Immunisation
and Surveillance in Europe

PROMISE, a new IMI funded project aimed at making a major leap forward in the fight against Respiratory Syncytial Virus (RSV), kicked off. Building on results generated by RESCEU, a previous IMI project also participated by Teamit, PROMISE is paving the way to RSV disease prevention, treatment and immunisation in Europe by generating new knowledge and data. Teamit was fully involved in the proposal stage and once funded, leads on general management, communication, dissemination, sustainability and alliance management. [Learn more about PROMISE here.](#)



Update on Ongoing Projects




In a difficult context marked by COVID-19, the RESCEU Consortium made significant advances on RSV research during 2021. This respiratory virus causes a common infection that can lead to serious disease and even death in vulnerable groups such as very young children and the elderly. RESCEU generated revised RSV disease medical, economic and social burden estimates and developed a sustainable data platform to quantify healthcare and economic impact of RSV and inform policy and regulatory processes. This Consortium also established a biobank for identifying potential biomarkers of RSV disease severity for further validation.

Teamit's contributions focused mainly in the areas of management, community building and engagement and dissemination of knowledge. In close collaboration with the Patient Advisory Board (PAB), it implemented communication campaigns to raise awareness about RSV. Visit [RESCEU website](#) for more information.



EU-PEARL continued developing a generic framework and a set of tools to conduct collaborative platform trials. In this type of clinical trials, several medicines can be tested simultaneously and sequentially. During 2021, the project generated templates, guidance documents and other resources to contribute to accelerate access to new and more effective treatments.

Teamit led on management and on communication and dissemination tasks. It was also directly involved in the design of the sustainability and exploitation strategy. Visit [EU-PEARL website](#) for more information.



H₂O

With the aim of strengthening patients' voice in health care by incorporating their reported outcomes in treatment decisions, H₂O made significant progress during 2021. The Consortium launched a Delphi process to reach consensus on a standardised language, started devising a governance model to ensure the safe and ethical storage of the data collected by national observatories and kicked off the process to design a data infrastructure with external technological partners.

Teamit provided its expertise on project management and in communication and dissemination. Furthermore, Teamit's CEO, Eva Molero co-authored the article "[Building a Value-Based Care Infrastructure in Europe: The Health Outcomes Observatory](#)" published in NEJM Catalyst Innovations in Care Delivery. Visit [H₂O website](#) for more information.



PREMIER

PREMIER advanced towards its goal of minimising the overall impact of medicines in the environment. During 2021 it started laying the foundations to build an Active Pharmaceutical Ingredients (API) information and assessment system for characterising the potential environmental risks of APIs. A call for data was launched to identify and prioritise legacy APIs suspected to represent a high risk, but for which an unambiguous conclusion cannot be drawn due to lack of data.

Teamit implemented the operational strategy to ensure in-depth scientific debate, collaboration and knowledge sharing within the Consortium. It also led on digital communication activities through website, social media and e-mail updates on project progress. Visit [PREMIER website](#) for more information.

PARTNERSHIPS



teamit
INSTITUTE

A crucial milestone achieved in 2021 was the creation of **Teamit Institute** as a spin-off of Teamit Research to reinforce the area of partnerships. The new entity builds on our previous experience and provides a more holistic expertise in scientific study management of pharmacoepidemiology research and regulatory science initiatives, including scientific advice with the EMA.

This area was put in the spotlight during the pandemic, highlighting the importance of monitoring and assessing the safety and effectiveness of medicines, vaccines and health technologies based on real world evidence to improve public health.

New
Head of
Partnerships
in 2021.



Gianmarco Di Mauro, MSc, PhD



UPDATE ON NETWORKS



Vaccine monitoring Collaboration for Europe



This international multistakeholder network promotes real-world evidence creation on vaccine coverage, safety, and effectiveness to support public health and decision making. VAC4EU has 24 members, from 9 European countries, and 17 data access providers covering an overall population of 152 million.

This European collaboration framework conducts multi-database studies to answer pharmacoepidemiologic and drug safety questions, covering about 20 million active population. It includes over 40 European and worldwide partners, from academia, industry, regulatory agencies, and health authorities.

HIGHLIGHTS

- Teamit became a full member of VAC4EU
- Eva Molero, appointed member of the Executive Board
- Support to business development and study acquisition, design, workplan and budgeting
- Scientific management of vaccine safety studies

In 2021 we consolidated our role in pharmacoepidemiology studies, not strictly linked to drug safety. We were also involved in the scientific management of pharmacovigilance studies to assess and follow up drug safety of authorised drugs generally required by EMA. In this regard, we participated in studies linked to musculoskeletal and respiratory diseases. Visit the EU-ADR Alliance dedicated page for more information.

SCIENTIFIC ADVICE

During 2021, we increased our activity in this area focused on getting regulatory feedback in relation to new methodologies, drugs, therapies, etc. We offered expert guidance to different world-class international organisations and initiatives, facilitating interaction with the EMA to obtain regulatory advice for the development of novel methodologies, techniques and medicinal products.



// THE YEAR AHEAD

With the roll out of HE and the increased focus on pharmacovigilance, 2022 is looking bright. At Teamit we are ready to embrace new challenges and opportunities and continue adapting our structure and expertise to changing needs in the European Health Research Ecosystem.

In this sense, we will welcome the Innovative Health Initiative (IHI). The newly created public-partnership takes over the Innovative Medicines Initiative (IMI) joint undertaking in which Teamit has long-standing experience. The new PPP will encompass new partners to cover a broader range of sectors such as vaccines, biotechnology and medical devices will operate under an updated governance structure. New calls are expected to open in the first half of 2022.

Besides, following up any calls centred around health, digitalisation and the environment launched by HE and IHI in the upcoming months, we will also keep an

eye on the development of the European Health Data Space which will have a major impact on our activities.

From Teamit Institute, we will closely monitor the roll out of the European Regulatory Science Strategy 2025 which will mark medicine development and assessment processes of innovative therapies and diagnostics based on new technologies. As experts in regulatory science, we will continue engaging with EMA to seek guidance and translate the approved strategy into studies. Furthermore, we will keep track of COVID-19 vaccination programmes across Europe through our continuous participation on post-marketing authorisation monitoring and studies.

We look forward to continuing developing far reaching proposals and building strong consortia with current and new partners this 2022. Visit our website to stay tuned.

tea.mit

RESEARCH

Visit our [website](#).



Partnerships for
Better Health Research